Incyte's Opzelura Nears EU Approval, Offering Hope for Chronic Eczema

MORGES, Switzerland – June 26, 2026 – In a move that could reshape the therapeutic landscape for millions of Europeans living with chronic skin disease, Incyte announced today that its Opzelura® (ruxolitinib) cream has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP). The recommendation is for the treatment of moderate atopic dermatitis in adults for whom conventional topical therapies have proven inadequate, marking a critical step toward the approval of the first non-steroidal topical JAK inhibitor for this condition in the European Union.

The decision, which now moves to the European Commission (EC) for final review, is more than a regulatory milestone; it represents a potential paradigm shift for a patient population often trapped between the limitations of traditional creams and the risks of powerful systemic drugs. If approved, Opzelura would offer a targeted, localized treatment that addresses both the visible inflammation and the debilitating itch that define atopic dermatitis.

Addressing a Critical Treatment Gap

Atopic dermatitis (AD), the most common form of eczema, is a chronic inflammatory condition affecting up to 7.1% of adults in Europe. Far from being a simple rash, it is a relentless disease characterized by dry, cracked skin, red lesions, and, most notably, a severe and persistent itch. This itch is often the most burdensome symptom, leading to a vicious scratch-itch cycle that damages the skin barrier, increases the risk of infection, and profoundly disrupts sleep, mental health, and overall quality of life.

For decades, the standard of care has been a step-wise approach beginning with topical corticosteroids (TCSs). While effective for short-term flare-ups, their long-term use is fraught with concerns over side effects like skin thinning and systemic absorption. This has led to a well-documented phenomenon of “steroid phobia” among patients. The next line of defense, topical calcineurin inhibitors (TCIs), can cause burning or stinging and may not be potent enough for many.

This leaves a significant treatment gap for patients with moderate disease who are not adequately controlled by these options but are not yet candidates for, or wish to avoid, systemic therapies like biologics or oral JAK inhibitors, which carry their own set of risks and monitoring requirements. Opzelura is positioned to fill this precise void.

The CHMP's positive opinion was based on data from the pivotal Phase 3 TRuE-AD program, including the TRuE-AD4 study. Results showed that ruxolitinib cream delivered statistically significant improvements in skin clearance and itch reduction. A remarkably high proportion of patients achieved at least a 75% improvement in the Eczema Area and Severity Index (EASI75), a key measure of disease severity. Crucially, patients experienced rapid itch relief, with some reporting improvements as early as Day 2. This efficacy was maintained over 24 weeks, and patients also reported substantial improvements in their quality of life.

“In clinical practice, many adults with moderate AD do not achieve the level of disease control they need, despite available topical therapies, and the impact on quality of life can be considerable,” said Dr. Andreas Wollenberg, Professor of Dermatology and Allergy at University Hospital Augsburg, Germany. “The data supporting this positive CHMP opinion suggest that ruxolitinib cream may offer an effective new topical treatment option for appropriate adult patients in Europe and may help delay or prevent progression to systemic therapy.”

The Science of Targeted Treatment

Opzelura’s innovation lies in its mechanism of action. As a topical Janus kinase (JAK) inhibitor, it represents the application of precision medicine to dermatology. JAKs are intracellular enzymes that play a crucial role in the signaling pathways of cytokines—proteins that drive the inflammation and itch characteristic of atopic dermatitis. By selectively inhibiting JAK1 and JAK2 enzymes within the skin, Opzelura disrupts this signaling cascade at the source.

This targeted approach contrasts sharply with the broad anti-inflammatory action of corticosteroids. According to independent dermatological experts, this allows for potent efficacy while minimizing the off-target effects associated with long-term steroid use. The topical formulation is key to its safety profile. While oral JAK inhibitors have proven highly effective for severe AD, they come with warnings for serious side effects due to their systemic action. By delivering ruxolitinib directly to the skin, Opzelura aims to provide localized relief with minimal systemic absorption.

This favorable safety profile was evident in the clinical trials. During the 24-week treatment period of the TRuE-AD4 study, no serious infections, major adverse cardiovascular events, malignancies, or thromboses were reported. The most common adverse events were mild, such as upper respiratory tract infections, highlighting the cream's tolerability.

Incyte’s Strategic Play in European Dermatology

For Incyte, a biopharmaceutical company that built its reputation in oncology and hematology, the pending approval represents a significant strategic victory and a deepening of its foray into the competitive inflammation and autoimmunity space. Following the EC’s final decision, which is anticipated within the next two to three months, Opzelura could see its second indication approved in the EU. It was first approved in 2023 for treating non-segmental vitiligo, another chronic skin condition.

Securing an indication for atopic dermatitis, a far more prevalent condition, would substantially expand Opzelura’s commercial potential in Europe. It allows Incyte to leverage its existing dermatology sales force and build a formidable franchise. This move solidifies the drug's blockbuster potential, which has already seen strong uptake in the United States, where it is approved for both AD and vitiligo.

Lee Heeson, Executive Vice President and Head of Incyte International, emphasized the unmet need. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.”

The positive CHMP opinion is a testament to Incyte's ability to identify and execute on high-value targets outside its traditional core. By successfully translating the science of JAK inhibition into a topical formulation, the company is not only providing a new tool for dermatologists but also building a diversified portfolio that promises sustained growth and connects the dots between advanced biological understanding and tangible patient benefit.